Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HUMBERTO J HERNANDEZ

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1689647869
CMS profile
211576
Location
HIALEAH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$778.36

49 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $778.36 49

By paying entity

PY2020 · entire year · sorted by reported total

Page 1 of 1; records 1–49 of 49 matching records. This page contains 49 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HUMBERTO J HERNANDEZ

NPI 1689647869 · CMS profile ID 211576

Allopathic & Osteopathic Physicians / Internal Medicine

HIALEAH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–49 of 49 matching records. This page contains 49 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1689647869?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HUMBERTO J HERNANDEZ, NPI 1689647869, CMS profile ID 211576. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–49 of 49 matching records. This page contains 49 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1689647869?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). HUMBERTO J HERNANDEZ, NPI 1689647869, CMS profile ID 211576. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–49 of 49 matching records. This page contains 49 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1689647869?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
HUMBERTO J HERNANDEZ, NPI 1689647869, CMS profile ID 211576, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–49 of 49 matching records. This page contains 49 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1689647869?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

49 matching records · $778.36 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 49 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–49 of 49.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $4.3312/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738807971 CMS
Amarin Pharma Inc. $21.7812/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 740003219 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $20.8212/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737540907 CMS
AstraZeneca Pharmaceuticals LP $19.5511/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735876685 CMS
Sunovion Pharmaceuticals Inc. $19.4411/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748508347 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.6210/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737540905 CMS
Sunovion Pharmaceuticals Inc. $23.0910/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748508351 CMS
Astellas Pharma US Inc $15.6110/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718333051 CMS
AstraZeneca Pharmaceuticals LP $13.8410/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735837137 CMS
Mylan Specialty L.P. $13.6210/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751401263 CMS
AbbVie Inc. $17.9810/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721869931 CMS
GlaxoSmithKline, LLC. $1.7010/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738618637 CMS
GlaxoSmithKline, LLC. $18.7810/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738800105 CMS
GlaxoSmithKline, LLC. $16.0009/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738876291 CMS
Mylan Specialty L.P. $12.5009/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751402433 CMS
SCILEX PHARMACEUTICALS INC. $18.3909/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752401203 CMS
AstraZeneca Pharmaceuticals LP $20.4309/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736294949 CMS
GlaxoSmithKline, LLC. $15.6009/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738623665 CMS
AbbVie Inc. $15.9208/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721869927 CMS
Astellas Pharma US Inc $18.6508/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718333049 CMS
AstraZeneca Pharmaceuticals LP $15.5408/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736384837 CMS
AstraZeneca Pharmaceuticals LP $2.7608/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735767897 CMS
GlaxoSmithKline, LLC. $1.3207/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738518277 CMS
GlaxoSmithKline, LLC. $15.7207/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738744535 CMS
Allergan, Inc. $20.7007/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723496645 CMS
AstraZeneca Pharmaceuticals LP $17.6607/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736061243 CMS
Astellas Pharma US Inc $20.4807/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718333047 CMS
Paratek Pharmaceuticals, Inc. $22.0106/24/2020 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 726896627 CMS
GlaxoSmithKline, LLC. $12.8506/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738652365 CMS
Amarin Pharma Inc. $18.5806/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739899117 CMS
Allergan, Inc. $17.6105/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723496643 CMS
Allergan, Inc. $16.0605/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723496641 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $23.1305/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720988733 CMS
AstraZeneca Pharmaceuticals LP $20.3705/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736280745 CMS
Sunovion Pharmaceuticals Inc. $18.4504/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748508341 CMS
Amarin Pharma Inc. $13.3004/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 740003221 CMS
Paratek Pharmaceuticals, Inc. $19.1704/28/2020 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 726896625 CMS
GlaxoSmithKline, LLC. $10.8204/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738518737 CMS
AstraZeneca Pharmaceuticals LP $11.7604/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736278601 CMS
Allergan, Inc. $17.4804/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723496639 CMS
GlaxoSmithKline, LLC. $15.9304/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738954301 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $23.4803/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737540903 CMS
GlaxoSmithKline, LLC. $18.9103/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738751601 CMS
GlaxoSmithKline, LLC. $10.9903/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738605103 CMS
Astellas Pharma US Inc $18.0301/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718333045 CMS
GlaxoSmithKline, LLC. $8.4401/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738803489 CMS
Mylan Specialty L.P. $15.7301/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751408293 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $13.4401/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737540901 CMS
AstraZeneca Pharmaceuticals LP $11.9901/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736357477 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $991.70 41
PY2020 $778.36 49
PY2021 $1,346.45 72
PY2022 $2,392.79 97
PY2023 $2,428.33 110
PY2024 $2,626.93 107
PY2025 $1,935.06 77

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $6,686.24 5
PY2022 Principal investigator $52,690.67 5
PY2021 Principal investigator $1,001,888.80 21

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

21 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $4,023.50 12/24/2021 Non-covered Recipient Entity
Sunrise Research Institute Inc
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 832553231
Principal investigator 1 PFIZER INC. $1,397.50 12/24/2021 Non-covered Recipient Entity
Sunrise Research Institute Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832553911
Principal investigator 1 PFIZER INC. $1,075.00 12/07/2021 Non-covered Recipient Entity
Sunrise Research Institute Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832553761
Principal investigator 1 PFIZER INC. $4,023.50 11/16/2021 Non-covered Recipient Entity
Sunrise Research Institute Inc
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 832616309
Principal investigator 1 PFIZER INC. $2,795.00 11/16/2021 Non-covered Recipient Entity
Sunrise Research Institute Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832722057
Principal investigator 1 PFIZER INC. $10,750.00 11/16/2021 Non-covered Recipient Entity
Sunrise Research Institute Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832797467
Principal investigator 1 PFIZER INC. $2,466.75 11/09/2021 Non-covered Recipient Entity
Sunrise Research Institute Inc
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 832616329
Principal investigator 1 PFIZER INC. $9,675.00 11/09/2021 Non-covered Recipient Entity
Sunrise Research Institute Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832764325
Principal investigator 1 PFIZER INC. $36,094.50 11/09/2021 Non-covered Recipient Entity
Sunrise Research Institute Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832865217
Principal investigator 1 PFIZER INC. $64,353.60 11/04/2021 Non-covered Recipient Entity
Sunrise Research Institute Inc
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 832616319
Principal investigator 1 PFIZER INC. $98,601.10 11/04/2021 Non-covered Recipient Entity
Sunrise Research Institute Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832701727
Principal investigator 1 PFIZER INC. $327,747.00 11/04/2021 Non-covered Recipient Entity
Sunrise Research Institute Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832862315
Principal investigator 1 PFIZER INC. $2,000.00 10/19/2021 Non-covered Recipient Entity
Sunrise Research Institute Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832887439
Principal investigator 1 PFIZER INC. $2,000.00 10/13/2021 Non-covered Recipient Entity
Sunrise Research Institute Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832718973
Principal investigator 1 PFIZER INC. $132,569.45 10/13/2021 Non-covered Recipient Entity
Sunrise Research Institute Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832842707
Principal investigator 1 PFIZER INC. $2,000.00 10/05/2021 Non-covered Recipient Entity
Sunrise Research Institute Inc
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 832616525
Principal investigator 1 PFIZER INC. $291,781.10 09/30/2021 Non-covered Recipient Entity
Sunrise Research Institute Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832732707
Principal investigator 1 PFIZER INC. $2,000.00 09/25/2021 Non-covered Recipient Entity
Sunrise Research Institute Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832811541
Principal investigator 1 PFIZER INC. $920.00 09/20/2021 Non-covered Recipient Entity
SUNRISE RESEARCH INSTITUTE
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 832602199
Principal investigator 1 PFIZER INC. $113.80 09/20/2021 Non-covered Recipient Entity
SUNRISE RESEARCH INSTITUTE
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 832602209
Principal investigator 1 PFIZER INC. $5,502.00 08/18/2021 Non-covered Recipient Entity
SUNRISE RESEARCH INSTITUTE
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832867065